1. Belimumab did not reduce risk of PSE compared with placebo (HR, 1.07; 95% CI, 0.44 to 2.59; P = 0.884)2. Belimumab did not reduce vasculitis relapse compared with placebo (HR, 0.88; 95% CI, 0.29 to 2.65; P = 0.821)3. All vasculitis relapses in belimumab group (N=6) occurred in PR3-ANCA patients with CYC induction4. Vasculitis relapse in the placebo group (N=8) occurred independent of induction agent, disease stage, or ANCA type5. Overall frequency of PSEs low (18.9% in belimumab group versus 21.2% in placebo group). The gene discussed is PRTN3; the disease is vasculitis.